Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. (2021)
Attributed to:
The impact of IFTIM3 genetic variation on Influenza virus infection, immune responses and disease outcome
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32661-1
PubMed Identifier: 33306989
Publication URI: http://europepmc.org/abstract/MED/33306989
Type: Journal Article/Review
Volume: 397
Parent Publication: Lancet (London, England)
Issue: 10269
ISSN: 0140-6736